Nano String Technologies Inc NSTG
We take great care to ensure that the data presented and summarized in this overview for NanoString Technologies Inc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NSTG
View allLatest Institutional Activity in NSTG
Top Purchases
Top Sells
About NSTG
NanoString Technologies, Inc. develops, manufactures, and sells tools for scientific and clinical research in the fields of genomics and proteomics in the Americas, Europe, the Middle East, and the Asia Pacific. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter MAX and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; panels with oncology, immunology and infectious disease, and neuroscience applications. Further, the company offers Master Kits, such as ancillary reagents and plasticware to setup and process samples in the nCounter Prep Station and nCounter Digital Analyzer; and Prosigna molecular diagnostic test kits. The company is also developing GeoMx DSP system to enable the field of spatial genomics. It has collaboration with Lam Research Corporation for the research and development of Hyb & Seq technologies; Celgene Corporation for developing LymphMark, an in vitro diagnostic for the treatment of diffuse large B-cell lymphoma; and Parker Institute for Cancer Immunotherapy to develop CAR-T regimens that enhances patient outcomes for various types of cancer. NanoString Technologies, Inc. was incorporated in 2003 and is headquartered in Seattle, Washington.
Insider Transactions at NSTG
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 06
2024
|
Elisha W Finney Director |
BUY
Exercise of conversion of derivative security
|
Direct |
41,133
+39.66%
|
-
|
May 06
2024
|
William Young Director |
BUY
Exercise of conversion of derivative security
|
Direct |
41,133
+28.6%
|
-
|
May 06
2024
|
Kirk Malloy Director |
BUY
Exercise of conversion of derivative security
|
Direct |
41,133
+38.62%
|
-
|
May 06
2024
|
R Bradley Gray President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
617,230
+17.65%
|
-
|
May 06
2024
|
Charles P Waite Jr Director |
BUY
Exercise of conversion of derivative security
|
Direct |
41,133
+34.16%
|
-
|
May 06
2024
|
Jonathan Todd Garland Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
200,000
+50.0%
|
-
|
May 06
2024
|
Gregory Norden Director |
BUY
Exercise of conversion of derivative security
|
Direct |
41,133
+31.72%
|
-
|
May 06
2024
|
Teresa M. Foy Director |
BUY
Exercise of conversion of derivative security
|
Direct |
44,975
+32.17%
|
-
|
May 06
2024
|
Dana E. Rollison Director |
BUY
Exercise of conversion of derivative security
|
Direct |
41,133
+39.85%
|
-
|
May 06
2024
|
Janet George Director |
BUY
Exercise of conversion of derivative security
|
Direct |
41,133
+39.85%
|
-
|
May 06
2024
|
K Thomas Bailey Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
182,702
+18.53%
|
-
|
May 06
2024
|
Joseph M Beechem SVP, Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
147,853
+15.09%
|
-
|
Apr 18
2024
|
Teresa M. Foy Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,841
+27.52%
|
-
|
Mar 08
2024
|
Dana E. Rollison Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,676
+7.41%
|
-
|
Mar 08
2024
|
Janet George Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,676
+7.41%
|
-
|
Mar 05
2024
|
R Bradley Gray President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
152,565
+9.42%
|
-
|
Mar 05
2024
|
K Thomas Bailey Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
46,073
+11.54%
|
-
|
Mar 05
2024
|
Joseph M Beechem SVP, Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
46,073
+9.98%
|
-
|
Sep 01
2023
|
R Bradley Gray President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
287
+0.08%
|
$574
$2.19 P/Share
|
Sep 01
2023
|
Joseph M Beechem SVP, Research & Development |
BUY
Grant, award, or other acquisition
|
Direct |
564
+0.59%
|
$1,128
$2.19 P/Share
|
Last 12 Months Summary
Exercise of conversion of derivative security | 1.73M shares |
---|